Head and Neck Cancer Study Project in the Geriatric Population

This study tests a modified treatment approach for older adults (65+) with head and neck cancer, combining immunotherapy (pembrolizumab) with standard chemoradiation therapy, guided by a comprehensive geriatric assessment to ensure the treatment is appropriate for each patient's overall health. **You may be eligible if...** - You are 65 or older with confirmed squamous cell carcinoma of the head and neck - Your cancer is Stage IB–IVA (locally advanced, not yet metastatic) - Your geriatric assessment score (CGA) falls in the 3–5 range - Your organ function and blood counts are adequate - You have been evaluated by both medical oncology and radiation oncology **You may NOT be eligible if...** - You have already received systemic chemoimmunotherapy for head and neck cancer - You have metastatic disease (cancer spread to other organs including the brain) - You have uncontrolled intercurrent illness - You have a history of severe autoimmune disease that would prevent immunotherapy Talk to your doctor to see if this trial is right for you.